ImmunityBio, Inc.
NASDAQ:IBRXBiotechnology
+$0.18 today
- Market cap
- $7.13B
- Beta
- 0.10
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.83
Volume 15.77M
Average 16.40M
IBRX Account Payables
Amounts the company owes suppliers for goods and services received.
ImmunityBio, Inc.NASDAQ: IBRX
Account Payables · Q3 FY2026 · quarter ended Sep 2026
Account payables rises 139.7% from a year ago
Account payables stood at $13.84M at the end of Q3 FY2026, up 139.7% from a year earlier and up 15.3% from the prior quarter. Over 3 fiscal years it compounded at -30.8% a year.
Context
- Account payables amounted to 2.3% of total assets at the end of Q3 FY2026, up 1.2 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +139.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 6.98M USD
- Year-over-year change
- +3.8%
- 4-year CAGR
- -11.6%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.98M | +3.8% |
| FY2024 | 2024-12-31 | 6.73M | -26.9% |
| FY2023 | 2023-12-31 | 9.2M | -56.2% |
| FY2022 | 2022-12-31 | 21.02M | +84.1% |
| FY2021 | 2021-12-31 | 11.42M | — |
Account Payables vs competitors
How IBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +139.7% is the highest of 11, against a peer median of +0.6%.
- Account payables amounts to 2.3% of total assets for IBRX, versus a peer median of 2.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | €646.43M EUR | +28.2% | +37.9% | 3.2% | |
| Sep 2026 | $259M USD | -3.0% | -13.3% | 1.9% | |
| Sep 2026 | $72M USD | -29.7% | +36.8% | 4.3% | |
| Mar 2026 | $30.16M USD | +3.6% | +19.0% | 2.8% | |
| Sep 2026 | $21.65M USD | -30.7% | -5.9% | 2.2% | |
| Sep 2026 | $13.84M USD | +139.7% | -30.8% | 2.3% | |
| Mar 2026 | €8.06M EUR | +37.6% | -56.1% | 1.5% | |
| Mar 2026 | $5.45M USD | +46.2% | +15.1% | 0.5% | |
| Mar 2026 | $4.93M USD | -2.5% | -32.5% | 1.2% | |
| Mar 2026 | $1.59M USD | +6.4% | +5.9% | 0.4% | |
| Mar 2026 | $637K USD | -54.0% | -73.6% | 3.2% | |
| Peer median (excluding IBRX) | — | +0.6% | -0.0% | 2.1% | |
Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 181.1M | 104.64M | 265.45M | 143.43M | 88.33M |
| Short-term Investments | 136.02M | 2.54M | 1.01M | 6.38M | 154.48M |
| Net Receivables | 1.33M | 1.89M | 3.17M | 2.65M | 42.62M |
| Inventory | 0 | 0 | 0 | 8.27M | 910K |
| Other Current Assets | 2.96M | 2.9M | 5.21M | 1.3M | 3.89M |
| Total Current Assets | 334.35M | 140.58M | 294.08M | 184.59M | 314.88M |
| Property, Plant & Equipment (Net) | 119.17M | 189.45M | 182.68M | 170.46M | 147.55M |
| Goodwill | 0 | 0 | 0 | 910K | 910K |
| Intangible Assets | 1.42M | 20M | 17.09M | 15.02M | 13.04M |
| Long-term Investments | 7.6M | 840K | 891K | 700K | 10.48M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 6.38M | 11.49M | 9.7M | 11.26M | 15.05M |
| Total Non-current Assets | 134.56M | 221.78M | 210.37M | 198.35M | 187.02M |
| Total Assets | 468.91M | 362.36M | 504.45M | 382.93M | 501.9M |
| Account Payables | 11.42M | 21.02M | 9.2M | 6.73M | 6.98M |
| Short-term Debt | 299.24M | 431.9M | 0 | 0 | 9.29M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 16.52M | 19.74M | 18.31M | 15.98M | 25.42M |
| Total Current Liabilities | 369M | 500.86M | 58.28M | 54.94M | 61.75M |
| Long-term Debt | 306.35M | 241.27M | 681.54M | 461.88M | 835.16M |
| Deferred Tax Liabilities | 162K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 249K | 22.09M | 310.63M | 319.42M | 70.89M |
| Total Non-current Liabilities | 343.83M | 311.32M | 1.03B | 816.12M | 939.72M |
| Total Liabilities | 712.82M | 812.18M | 1.09B | 871.06M | 1B |
| Common Stock | 40K | 42K | 67K | 85K | 101K |
| Retained Earnings | (1.96B) | (2.38B) | (2.96B) | (3.38B) | (3.73B) |
| Accumulated OCI | 4K | 183K | 10K | 1.2M | 28.96M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 909K |
| Minority Interest | (1.74M) | (2.49M) | 1.05M | 969K | 895K |
| Total Equity | (243.91M) | (449.82M) | (585.94M) | (488.13M) | (499.57M) |
| Total Debt | 645.66M | 723.77M | 726.72M | 504.17M | 878.12M |
| Net Debt | 464.56M | 619.13M | 461.27M | 360.74M | 789.78M |
ImmunityBio, Inc.
NASDAQ:IBRX
Intrinsic Alpha fair value
Locked
Current Price
$6.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.